Melatonin: From basic research to cancer treatment clinics

Journal of Clinical Oncology

Volumn 20, Issue 10, 2002, Pages 2575-2601

  Vijayalaxmi, ^a   Thomas Jr , Charles R ^a   Reiter, Russel J ^a   Herman, Terence S ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHOXYTRYPTAMINE; 5 METHOXYTRYPTOPHOL; 6 HYDROXYMELATONIN; CELL DNA; DIMETHYLBENZ[A]ANTHRACENE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; MELATONIN; MELATONIN RECEPTOR; N ACETYLSEROTONIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXY RADICAL; SEROTONIN; SINGLET OXYGEN; TRYPTOPHAN;

ANTIOXIDANT ACTIVITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INHIBITION; CELL PROTECTION; CELL STRAIN MCF 7; CLINICAL TRIAL; CONFUSION; DROWSINESS; ENZYME ACTIVITY; FATIGUE; HORMONAL REGULATION; HUMAN; IMMUNOMODULATION; LEUKEMIA; LIPID PEROXIDATION; LYMPHOMA; MELANOMA; NEUROENDOCRINOLOGY; NONHUMAN; OXIDATIVE STRESS; PINEAL BODY; PRIORITY JOURNAL; RADIATION INJURY; REVIEW; SARCOMA;

ANIMALS; ANTIOXIDANTS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; FREE RADICAL SCAVENGERS; HUMANS; MELATONIN; NEOPLASMS;

EID: 0037093071     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.11.004     Document Type: Review

References (466)

1. The pineal and its hormones in the control of reproduction in mammas
2. Isolation of melatonin, a pineal gland factor that lightens melanocytes
3. Structure of melatonin
4. Enzymatic O-methylation of N-acetyl-serotonin to melatonin
5. Biosynthesis of melatonin: Enzymatic conversion of serotonin to N-acetylserotonin
6. Circadian changes in rat pineal tryptophan content: Lack of correlation with serum tryptophan
7. Pineal melatonin: All biology of its synthesis and of its physiological interactions
8. Indole metabolism in the pineal gland: A circadian rhythm in N-acetyltransferase
9. A circadian rhythm of tryptophan hydroxylase in rat pineals
10. Diurnal rhythm and turnover of tryptophan hydroxylase in pineal gland of rat
11. Fine structure of granular vesicles in pineal autonomic nerve endings after serotonin depletion
12. Melatonin: The chemical expression of darkness
13. Circadian rhythm in the serotonin content in the pineal gland: Regulating factors
14. Diurnal variation in the serotonin content and turnover in the pineal gland of the Syrian hamster
15. Extra-pineal melatonin in the retina: Its regulation and physiological function
16. Melatonin in the lacrimal gland: First demonstration and experimental manipulation
17. 5-Aminolevulinate synthase mRNA levels in the Harderian gland of Syrian hamsters: Correlation with porphyrin concentrations and regulation by androgens and melatonin
18. Effect of tryptophan administration on circulating melatonin levels in chicks and rats: Evidence for stimulation of melatonin synthesis and release in the gastrointestinal tract
19. Melatonin and its receptors in the gastrointestinal tract
20. Identification of highly elevated levels of melatonin in bone marrow: Its origin and significance
21. Evidence for melatonin synthesis in mouse and human bone marrow cells
22. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat
23. Melatonin and other serotonin derivatives in the guinea pig membranous cochlea
24. The ciliary body: The third organ found to synthesize indoleamines in humans
25. The clock in the mouse retina: Melatonin synthesis and photoreceptor degeneration
26. Melatonin immunoreactivity in the prokaryote Rhodopirillum rubrum: Implications for an ancient oxidative system
27. Melatonin production in an aerobic photosynthetic bacterium: An evolutionarily early association with darkness
28. The pineal hormone melatonin oscillates also in the dinoflagellate Gonyaulax polyedra
29. Chronobiology of indoleamines in the dinoflagellate Gonyaulax polyedra: Metabolism and effects related to circadian rhythmicity and photoperiodism
30. Melatonin in edible plants identified by radioimmunoassay and by high performance liquid chromatography-mass spectrometry
31. Melatonin in plants
32. Detection and quantification of the antioxidant melatonin in Montmorency and Balatontant cherries (Pruneus ceracus)
33. Melatonin in plant organ
34. Melatonin identification in medicinal plants
35. Melatonin bio synthesis in Drosophila: Its nature and its effects
36. Identification of melatonin in the compound eye of the insect, the locust (Locusta migratoria), by radioimmunoassay and gas chromatography-mass spectrometry
37. Normal patterns of melatonin levels in the pineal gland and body fluids of humans and experimental animals
38. Direct radioimmunoassay of melatonin in saliva
39. Diurnal rhythm of melatonin in human saliva
40. Melatonin in human preovulatory follicular fluid
41. Melatonin and sperm motility
42. Serum and amniotic fluid melatonin during human labor
43. High physiological levels of melatonin in bile of mammals
44. High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood in recirculating through the choroids pleaxus
45. Melatonin cycle in plasma and cerebrospinal fluid of calves
46. Evidence of high concentrations of melatonin in lateral ventricular cerebrospinal fluid of sheep
47. Serum and cerebrospinal fluid concentrations of melatonin: A pilot study in healthy male volunteers
48. Melatonin high-affinity binding to alpha-1-acid glycoprotein in human serum
49. Circadian rhythm of free melatonin in human plasma
50. Transport of albumin-bound melatonin through the blood-brain barrier
51. Radioimmunoassay of bound and free melatonin in plasma
52. The correlation between serum and salivary melatonin concentrations and urinary 6-hydroxymelatonin sulphate excretion rates: Two non-invasive techniques for monitoring human circadian rhythmicity
53. Prediction of nocturnal plasma melatonin from morning urinary measures
54. A mathematical model of diurnal variations in human plasma melatonin levels
55. Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis
56. A once-repeated study of nocturnal plasma melatonin patterns and sleep recordings in six normal young men
57. Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection
58. The fate of melatonin in animals
59. Pharmacokinetics of melatonin in man: First pass hepatic metabolism
60. Melatonin is metabolized to N-acetyl serotonin and 6-hydroxymelatonin in man
61. Identification of 6-hydroxymelatonin in normal urine by gas chromatography-mass spectrometry
62. Urinary 6-sulfatoxymelatonin excretion and melatonin production rate: Studies in sheep and man
63. Biochemistry and regulation of mammalian melatonin production
64. Long-term studies on immunoreactive human melatonin
65. Correlation between salivary and serum melatonin: Dependence on serum melatonin levels
66. Low and high melatonin secretors among healthy individuals
67. 24-Hour profiles of melatonin, cortisol, insulin, e-peptide and GIP following a meal and subsequent fasting
68. Reproducibility of the overnight melatonin secretion pattern in healthy men
69. Melatonin secretion in humans assessed by measuring its metabolite, 6-sulfatoxymelatonin
70. Twenty-four-hour cycle of melatonin-like substance in the plasma of human males
71. The measurement of melatonin in mammalian tissues and body fluids
72. Melatonin radioimmunoassay
73. A gas chromatography-mass spectrometry method for the quantitative analysis of melatonin in plasma and cerebrospinal fluid
74. Pineal and plasma melatonin as determined by high-performance liquid chromatography with electrochemical detection
75. Melatonin levels are reduced in the pineal glands of suicide victims
76. Effect of photoperiod on the diurnal melatonin and 5-methoxytryptophol rhythms in the human pineal gland
77. Salivary melatonin assay in laboratory medicine-longitudinal profiles of secretion in healthy men
78. Salivary melatonin diurnal rhythm may be abolished after transmeridian flights in an eastward but not a westward direction
79. Melatonin rhythm in human milk
80. Twenty-four-hour rhythms in relation to the natural photoperiod: A field study in humans
81. The pineal gland and cancer: Facts, hypothesis and perspectives
82. Different types of melatonin circadian rhythms in some blind subjects
83. Relationship between napping and melatonin in the blind
84. Melatonin in circadian sleep disorders in the blind
85. Free-running rhythms of melatonin, cortisol, electrolytes, and sleep in humans in Antarctica
86. Complex effects of melatonin on human circadian rhythms in constant dim light
87. The pineal gland: A neurochemical transducer
88. Melatonin in humans: Physiological and clinical studies
89. Daily and annual rhythm in human melatonin secretion: Role in puberty control
90. Measurement of urinary production rates of melatonin as an index of human pineal function
91. Neuroendocrine effects of the pineal gland and of melatonin
92. HPLC validation of a circadian rhythm in the pineal gland of inbred mice
93. Developing circadian rhythmicity: Basic and clinical aspects
94. Development of melatonin production in infants and the impact of prematurity
95. Melatonin in human cerebrospinal fluid in daytime: Its origin and variation with age
96. Age- and mental health-related circadian rhythms of plasma levels of melatonin, prolactin, luteinizing hormone and follicle-stimulating hormone in man
97. Human melatonin production decreases with age
98. Annual changes in 6-sulphatoxymelatonin excretion in man
99. Age- and sex-associated modification of plasma melatonin concentrations in man: Relationship to pathology, malignant or not, and autopsy findings
100. Seasonal, menstrual and circadian secretions of melatonin, gonadotropins and prolactin in women
101. Patterns of plasma melatonin with ageing and mental condition: Stability of nyctohemeral rhythms and differences in seasonal variations
102. Seasonal variation of gonadotropins and gonadal steroid receptors in the human pineal gland
103. Factors influencing urinary 6-sulfatoxymelatonin, a major melatonin metabolite, in normal human subjects
104. Short-term fasting inhibits the nocturnal melatonin secretion in healthy man
105. Effects of fasting on plasma melatonin levels
106. Nocturnal plasma melatonin levels in migraine: A preliminary report
107. Impaired nocturnal secretion of melatonin in coronary heart disease
108. Urinary 6-hydroxymelatonin excretion in patients with orthostatic hypotension
109. Nocturnal plasma melatonin levels in schizophrenic patients
110. Melatonin in serum and urine in patients with idiopathic pain syndromes
111. Daily rhythm of serum melatonin in patients with dementia of the degenerate type
112. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype
113. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking
114. Plasma melatonin levels in depressed patients before and after treatment with antidepressant medication
115. Amplification of nocturnal melatonin secretion in women with functional hypothalamic amenorrhea
116. Changes in melatonin levels but not cortisol levels are associated with depression in patients with eating disorders
117. Melatonin secretion in Turner's syndrome: Lack of effect of oestrogen administration
118. Effects of low oral dose of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans
119. Melatonin: Clinical pharmacology
120. Sleep induction by intranasal application of melatonin
121. Transmucosal, oral controlled-release, and transdermal drug administration in human subjects: A crossover study with melatonin
122. Preliminary evaluation of transdermal delivery of melatonin in human subjects
123. Bioavailability of oral melatonin in humans
124. Plasma concentrations of melatonin in man following oral absorption of different preparations
125. Solubility of pure bilayers to melatonin
126. High melatonin solubility in aqueous media
127. Distribution of melatonin in mammalian tissues: The relative importance of cytosolic versus nuclear localization
128. Nuclear localization of melatonin in different mammalian tissues: Immunocytochemical and radioimmunoassay evidence
129. Modulation of subcellular distribution of calmodulin by melatonin in MDCK cells
130. How melatonin interacts with lipid layers: A study by fluorescence and ESR spectroscopies
131. Melatonin, mitochondria, and cellular bioenergetics
132. Gastric toxicity and mucosal ulceration induced by oxygen-derived reactive species: Protection by melatonin
133. Anticarcinogenic actions of melatonin which involve antioxidative processes: Comparison with other antioxidants
134. Pharmacological action of melatonin in shocks, inflammation and ischemia/reperfusion injury
135. Free radical-mediated molecular damage: Mechanisms for the protective actions of melatonin in the central nervous system
136. Reactive oxygen intermediaries, molecular damage and aging: Relation to melatonin
137. Melatonin reduces the oxidation of nuclear DNA and membrane lipids induced by the carcinogen delta-aminolevulinic acid
138. Actions of melatonin in the reduction of oxidative stress: A review
139. Melatonin protects fetal rat brain against oxidative mitochondrial damage
140. Melatonin protects against oxidized low-density lipoprotein-induced inhibition of nitric oxide production in human umbilical artery
141. Melatonin inhibits lipid peroxidation and stimulates the antioxidant status of diabetic rats
142. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses
143. Polymorphism and signaling of melatonin receptors
144. Melatonin receptors in the rat brain and pituitary
145. A molecular perspective of the genetic relationship of G-protein coupled melatonin receptor subtypes
146. Mapping of the gene for the Mella-melatonin receptor to human chromosome 4 (MTNR1 A) and mouse chromosome 8 (Mtnr1a)
147. Studies on the retinal action of melatonin: Evidence that the effects are mediated by 37 kDa receptors of the Mella subtype localized primarily to the basolateral membrane of the proximal tubule
148. Melatonin receptors are for the birds: Molecular analysis of two receptor subtypes differentially expressed in chick brain
149. Human malignant melanoma cells express high affinity receptors for melatonin: Antiproliferative effects of melatonin and 6-chloromelatonin
150. Melatonin receptors in purified cell nuclei of liver
151. Characterization of high-affinity melatonin binding sites in purified cell nuclei of rat liver
152. Pineal hormone melatonin binds and activates an orphan of the nuclear family superfamily
153. The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: An unexpected relationship
154. Both melatonin and a putative nuclear melatonin receptor agonist CGP 52608 stimulate glutathione peroxidase and glutathione reductase activities in mouse brain in vivo
155. The significance of the metabolism of the neurohormone melatonin: Protection and formation of bioactive substances
156. Melatonin, a mediator of electron transfer and repair reactions, acts synergistically with the chain-breaking antioxidant ascorbate, trolox, and glutathione
157. Significance of melatonin in antioxidative defense system: Reactions and products
158. Melatonin: Mechanisms and actions as an antioxidant
159. Molecular signaling via the melatonin receptor
160. 125I]iodomelatonin binding sites in the guinea pig spleen by melatonin injection is dependent on the dose and period but not time
161. Effects of melatonin on microtubule assembly depend on hormone concentration: Role of melatonin as a calmodulin antagonist
162. Physiological concentrations of melatonin inhibit nitric oxide synthase in the rat hypothalamus
163. Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation with colmodulin
164. Effects of pinealectomy on the in vivo and the in vitro biosynthesis of nucleic acids and on the mitotic rate in some organs of the rat
165. Histological changes in the lung, thymus, and adrenal one and half year after pinealectomy
166. Transient hypertrophy of the ventral prostate and coagulating glands and accelerated thymic involution following pinealectomy in the mouse
167. Immunocompetence of pinealectomized and simultaneously pinealectomized and thymectomized rats
168. Role of the pineal gland in immunity: Circadian synthesis and release of melatonin modulates the antibody response and antagonize the immunosuppressive effect of corticosterone
169. Spleen morphology and lymphoproliferative activity in short photoperiod exposed hamsters
170. Pinealectomy inhibits interleukin- 2 production and natural killer activity in mice
171. Modulation of antibody-dependent cellular cytotoxicity by pineal gland
172. The immunoneuroendocrine role of melatonin
173. Beta-endorphin and dynorphin mimic the circadian immunoenhancing and anti-stress effects of melatonin
174. The pineal neurohormone melatonin stimulates activated CD4+, Thy-1+ cells to release opioid agonist(s) with immunoenhancing and anti-stress properties
175. Anti-stress role of melatonin-immuno-opioid network: Evidence for a physiological mechanism involving T cell-derived immunoreactive b-endorphin and MET-enkephalin binding to thymic opioid receptors
176. Melatonin in relation to the immune system
177. Melatonin-induced enhancement of antibody dependent cellular cytotoxicity
178. Melatonin as immunomodulator in immunodeficient mice
179. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients
180. Melatonin increases antigen presentation and amplifies specific and non specific signals for T-cell proliferation
181. Activation of human monocytes by the pineal neurohormone melatonin
182. Melatonin and protection from genetic damage in blood and bone marrow: Wholebody irradiation studies in mice
183. The effect of melatonin on lipid peroxidation during radiotherapy in female rats
184. Potential radioprotective agents, 1: Homologues of melatonin
185. Melatonin and protection from whole-body irradiation: Survival studies in mice
186. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague Dawley rats
187. Acute pharmacology of melatonin
188. The effect of melatonin on in vitro fertilization and embryo development in mice
189. Constant darkness enhances autoimmunity to type 11 collagen and exaggerates development of collagen-induced arthritis in DBA/I mice
190. The pineal hormone melatonin exaggerates development of collagen-induced arthritis in mice
191. Role of pineal melatonin and melatonin-induced-immuno-opioids in murine leukemogenesis
192. Effects of melatonin on human mood and performance
193. Alleviation of jet lag by melatonin: Preliminary results of controlled double-blind trial
194. Endocrine and immune effects of melatonin therapy in metastatic cancer patients
195. Melatonin administration and insomnia
196. Influence of melatonin treatment on human circadian rhythmicity before and after a simulated 9-hour shift
197. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function and can inhibit ovulation
198. Neuroimmunotherapy of advanced solid neoplasm with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: Preliminary results
199. Melatonin and radioprotection from genetic damage: In vivo/in vitro studies with human volunteers
200. Melatonin reduces gamma radiation-induced primary DNA damage in human blood lymphocytes
201. The effects of oral melatonin on skin color and on the release of pituitary hormones
202. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment
203. Vitamin E consumption induced by oxidative stress in red blood cells is enhanced by melatonin and reduced by N-acetyl-serotonin
204. Melatonin as an antioxidant in retinal photoreceptors
205. A randomized study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma
206. Melatonin and the immune system
207. Melatonin involvement in immunity and cancer
208. Melatonin activates the lymphocytes by increasing IL- 2 production
209. Melatonin stabilizes sleep onset time in a blind man without entrainment of cortisol or temperature rhythms
210. The importance of timing in melatonin administration in a blind man
211. Long-term melatonin treatment in blind children and young adults with circadian sleep-awake disturbances
212. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: Assessment in a clinical trial of melatonin replacement
213. Effect of melatonin in selected populations of sleep-disturbed patients
214. Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag
215. Use of melatonin to treat sleep disorders in tuberous sclerosis
216. The effect of melatonin on normal sleep
217. On the effect of melatonin upon human brain: Its possible therapeutic implications
218. Effects of melatonin on mood and performance
219. Endogenous sleep-substances and sleep regulation
220. Use of melatonin for sleep and circadian rhythm disorders
221. The use of melatonin for the treatment of insomnia
222. Negative effects of melatonin on depression
223. Clinical trials of controlled released melatonin in children with sleep-wake cycle disorders
224. Effects of melatonin in septic newborns
225. Increased levels of melondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: Reduction by melatonin
226. Premedication with melatonin: A double blind, placebo-controlled comparison with midazolam
227. The acute soporific action of daytime melatonin administration: Effects on the EEG during wakefulness and subjective alertness
228. Melatonin for sleep EEG
229. Effect of pharmacological daytime doses of melatonin on human mood and performance
230. Effect of daytime oral melatonin administration on neurobehavioral performance in humans
231. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance
232. Day-time melatonin administration: Effects on core temperature and sleep onset latency
233. Treatment of circadian rhythm disordersmelatonin
234. Daytime melatonin and temazepam in young adult humans: Equivalent effects on sleep latency and body temperature
235. The acute soporific action of daytime melatonin administration: Effects on the EEGG during wakefulness and subjective alertness
236. The secretion and actions of melatonin
237. Sleep dysfunction in Rett syndrome: A trial of exogenous melatonin treatment
238. Melatonin
239. Melatonin involvement in oxidative stress
240. Melatonin: A potent, endogenous hydroxyl radical scavenger
241. Evaluation of the antioxidant activity of melatonin in vitro
242. Characterization of the antioxidant effects of melatonin and related indoleamines in vitro
243. Melatonin and structurally related endogenous indoles act as potent electron donors and radical scavenger in vitro
244. Scavenging effect of melatonin on hydroxyl radicals generated by alloxan
245. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: A biomarker of in vivo hydroxyl radical generation
246. Functional aspects of the pineal hormone melatonin in combating cell and tissue damage induced by free radicals: A review
247. Pharmacological actions of melatonin in free radical pathophysiology
248. Melatonin directly scavenges hydrogen peroxide: A potentially new metabolic pathway of melatonin biotransformation
249. N-acetyl-N-formyl-5-metoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant
250. Melatonin: A peroxyl radical scavenger more potent than vitamin E
251. Melatonin as an efficient antioxidant
252. On the antioxidant activity of melatonin
253. Protective effect of histidine during ischemia-reperfusion in isolated hearts
254. Oxidative damage in the liver induced by ischemia-reperfusion: Protection by melatonin
255. Melatonin protects neurons from singlet oxygen-induced apoptosis
256. The excited states of melatonin
257. Melatonin and its precursors scavenge nitric oxide
258. Nitrosation of melatonin by nitric oxide and peroxynitrite
259. Nitrosation of melatonin by nitric oxide: A computational study
260. The chemistry of peroxynitrite: A product from the reaction of nitric oxide with superoxide
261. Melatonin is a scavenger of peroxynitrite
262. Protective effect of melatonin in carrageenan-induced models of local inflammation
263. Melatonin prevents increases in neural nitric oxide and cyclic GMP production after transient brain ischemia and reperfusion in the Mongolian gerbil (meriones unguiculatus)
264. On the primary functions of melatonin in evolution: Mediation of photoperiodic signals in a unicell, photooxidation, and scavenging of free radicals
265. A review of the evidence supporting melatonin's role as an antioxidant
266. Melatonin in the context of the free radical theory of aging
267. Melatonin: Antioxidative protection by electron donation
268. Melatonin prevents changes in microsomal membrane fluidity during induced lipid peroxidation
269. Neurohormone melatonin prevents cell damage: Effect of gene expression for antioxidative enzymes
270. Melatonin increases gene expression for antioxidant enzymes in rat brain cortex
271. Melatonin stimulated brain glutathione peroxidase activity
272. Time course of melatonin-induced increase in glutathione peroxidase activity in chick tissues
273. Rhythms of glutathione peroxidase and glutathione reductase in the brain of chicks and their inhibition by light
274. Oxygen radicals, melatonin and aging
275. Antioxidative effect of melatonin in rat brain oxidative stress induced by adriamycin
276. Membrane oxidative damage induced by ionizing radiation detected by diphenylhexatriene fluorescence lifetime distributions
277. Evidence for an increase in water concentration in bilayers after oxidative damage of phospholipids induced by ionizing radiation
278. Antioxidant activity of melatonin in mice
279. Melatonin reduces kainate-induced lipid peroxidation in homogenates of different brain regions
280. Melatonin reduces both basal and bacterial lipopolysaccharide-induced lipid peroxidation in vitro
281. Melatonin administration prevents lipopolysaccharide-induced oxidative damage in phenobarbitol-treated animals
282. Lipopolysaccharide-induced hepatotoxicity is inhibited by the antioxidant melatonin
283. 2 induced lipid peroxidation in homogenates of different rat brain regions
284. Retinal lipid peroxidation in vitro is inhibited by melatonin
285. Pharmacology and physiology of melatonin in the reduction of oxidative stress
286. Melatonin versus vitamin E as protective treatment against oxidative stress after extra-hepatic bile duct ligation in rats
287. In vivo changes in antioxidant systems and of vitamin C and vitamin E on oxidative damage in erythrocytes induced by chlorpyrifos-ehtyl in rats
288. Individual and synergistic antioxidative actions of melatonin: Studies with vitamin E, vitamin C, glutathione and desferoxamine in liver homogenates
289. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: A review of the evidence
290. Melatonin: A highly potent endogenous radical scavenger and electron donor. New aspects of the oxidation chemistry of this indole assessed in vitro
291. Reaction of melatonin and related indoles with hydroxyl radicals: EPR and spin trapping investigations
292. Antioxidant properties of melatonin: A pulse radiolysis study
293. Mechanisms of action on the human immune system: Membrane receptors versus nuclear receptors
294. Mechanisms involved in the immunomodulatory effects of melatonin on the human immune system
295. Melatonin administration attenuates depressed immune functions in traumahemorrhage
296. The clinical neuroimmunotherapeutic role of melatonin in oncology
297. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin- 2 plus the neurohormone melatonin in gastrointestinal tract tumor patients
298. Melatonin-immune system relationships
299. Suppression of UV-induced erythemia by topical treatment with melatonin (N-acetyl-5-methoxytryptamine): A dose-response study
300. Topical melatonin in combination with vitamins E and C protects skin from ultraviolet-induced erythemia: A human study in vivo
301. Melatonin reduces UV-induced reactive oxygen species in a dose-dependent manner in IL-3-stimulated leukocytes
302. Melatonin protects human blood lymphocytes from radiation-induced chromosome damage
303. Marked reduction of radiation-induced micronuclei in human blood lymphocytes pretreated with melatonin
304. Effect of melatonin on mitotic and proliferation indices, and sister chromatid exchange in human blood lymphocytes
305. Melatonin: Possible mechanisms involved in its "radioprotective" effect
306. Radioprotective effect of melatonin assayed by measuring chromosomal damage in mitotic and meiotic cells
307. Protective effects of melatonin against oxidation of guanine bases in DNA and decreased microsomal membrane fluidity in rat liver induced by whole body ionizing radiation
308. Modulatory effects of melatonin on genotoxic response of reference mutagens in the Ames test and the comet assay
309. Melatonin protects human red cells from oxidative hemolysis: New insights into the radical-scavenging activity
310. The influence of melatonin in metabolic changes in female rats induced by continuous irradiation and/or administration of 7, 12-dimethylbenz(a)anthracene
311. Histoenzymological reactions of the thyroid gland in irradiated and previously melatonin-treated irradiated rats
312. Morphometric characteristics of thyroid cells in irradiation-stressed rats treated with pinealectomy and melatonin
313. The pineal neurohormone melatonin prevents in vivo and in vitro apoptosis in thymocytes
314. Pineal indolamines and vitamin E reduce nitric oxide-induced lipid peroxidation in rat retinal homogenates
315. Hemopoietic rescue via T-cell dependent, endogenous granulocyte-macrophage colony stimulating factor induced by the pineal neurohormone melatonin in tumorbearing mice
316. Morphometric aspects of seminiferous tubules in rats treated with melatonin and whole body irradiation
317. Morphometric characteristics of Leydig cells after total body irradiation of rats treated with melatonin
318. The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo
319. Structure-activity studies of the carcinogenesis in the mouse and rat of naturally occurring and synthetic alkenyl-benzene derivatives related to safrole and estragole
320. Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen safrole
321. Potent protective effect of melatonin on in vivo paraquat-induced oxidative damage in rats
322. Paraquat
323. Bipyridylium quaternary salts and related compounds, V: Pulse radiolysis studies of the reaction of paraquat radical with oxygen. Implications for the mode of action of bipyridyl herbicides
324. Correlation between lipid peroxidation and morphological manifestation of paraquat-induced lung injury in rats
325. Melatonin, a pineal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rats
326. The diffuse neuroendocrine system and extrapineal melatonin
327. Mitotic arrest by melatonin
328. The growth inhibitory action of melatonin on human breast cancer cells is linked to the oestrogen response system
329. Melatonin inhibits DNA dynthesis in MCF-7 human breast cancer cells in vitro
330. The pineal: An oncostatic gland?
331. The oncostatic and oncomodulatory role of the pineal gland and melatonin
332. Uber die nature und die Pathogenese der Krebstumren. Radikale Heilung de Krebses bei weiblichen Mauses
333. Pineal gland, cellular proliferation and neoplastic growth: An historical account
334. A human cell line from a pleural effusion derived from a breast carcinoma
335. Effects of melatonin on cancer: Studies on MCF-7 human breast cancer cells in culture
336. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture
337. Differences between pulsatile or continuous exposure to melatonin on MCF-7 human breast cancer cell proliferation
338. Effects of the pineal hormone melatonin on the anchorage-independent growth of human breast cancer cells (MCF-7) in a clonogenic system
339. Melatonin inhibition of MCF-7 human breast cancer cell growth: Influence of cell proliferation rate
340. Neurohormonal modulation of cancer growth by pineal melatonin
341. Melatonin modulates growth factor activity in MCF-7 human breast cancer cells
342. Influence of cell proliferation and cell phase on expression of estrogen receptor in MCF-7 breast cancer cells
343. Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro
344. Endocrine pharmacology of antiestrogens as antitumor agents
345. Effects of melatonin on the cell cycle kinetics and estrogen rescue of MCF-7 human breast cancer cells in culture
346. 5-Fluorouracil attenuates an oncostatic effect of melatonin on estrogen-sensitive human breast cancer (MCF-7)
347. Influence of pineal gland function on the initiation and growth of hormone-dependent breast tumors: Possible mechanisms
348. Effects of melatonin on experimental mammary cancer development
349. Melatonin An anticancer hormone of the pineal gland
350. Melatonin, hydroxyl radical-mediated oxidative damage and aging: A hypothesis
351. Chemical, oncogene and growth factor inhibition gap junctional intercellular communication: An integrative hypothesis of carcinogenesis
352. Melatonin enhances junctional transfer in normal CH3/1OT1/2 cells
353. Neuroendocrine and endocrine correlates to hamster melanoma growth in vitro
354. The link between the pineal gland and cancer: An interaction involving chronobiological mechanisms
355. Differential effect of melatonin on slow and fast growing passages of a human melanoma cell line
356. Melatonin inhibits proliferation and melanogenesis in rodent melanoma cells
357. Melatonin inhibits growth of cultured human uveal melanoma cells
358. Melatonin binding sites are functionally coupled to phosphoinositide hydrolysis in Syrian hamster RPMI 1846 melanoma cells
359. Estrogen and progesterone receptors and tamoxifen in malignant melanoma
360. The effect of tamoxifen on the growth of human malignant melanoma in vitro
361. Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen
362. Estrogen receptor in malignant melanoma
363. Growth inhibitory effects of melatonin and its metabolites against ovarian tumor cells in vitro
364. Inhibition of human ovarian cancer cell proliferation in vitro by neuroendocrine hormones
365. Growth inhibitory and cytotoxic effects of melatonin and its metabolites on human tumour cell lines in vitro
366. Antitumor activity of the pineal gland: Effect of unidentified substances versus the effect of melatonin
367. Melatonin's inhibitory effect on growth of ME-180 human cervical cancer cells is not related to intracellular glutathione concentrations
368. Effects of melatonin on the proliferation and differentiation of human neuroblastoma cells in culture
369. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide
370. Melatonin alters the metabolism of the b-amyloid precursor protein in the neuroendocrine cell line PC12
371. N-acetyserotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-kappaB
372. Melatonin inhibits the proliferation of estrogen-induced rat pituitary tumor cells in vitro
373. Melatonin antagonizes colchicines-induced mitotic arrest
374. Influence of environmental light and melatonin upon mammary tumor induction
375. Correlations of anti-tumor activity of pineal and hypothalamic extract, melatonin and sygethin in mouse transplantable mammary tumors
376. Role of the pineal gland in the aetiology and treatment of breast cancer
377. Melatonin circadian stagedependently delays breast tumor development in mice injected daily for several months
378. Melatonin, a suppressor of spontaneous murine mammary tumors
379. Effect of pinealectomy and melatonin on mammary tumor growth in Sprague Dawley rats under different conditions of lighting
380. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat
381. Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods
382. Inhibitory effects of the pineal hormone melatonin and underfeeding during promotional phase of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary tumorigenesis
383. Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-mehtylurea model of mammary carcinogenesis: Potential involvement of antiestrogenic mechanisms in vivo
384. Melatonin in oncology
385. Melatonin and cancer: Basic and clinical perspectives
386. Breast cancer: A target site for the oncostatic actions of pineal hormones
387. Influence of chronic melatonin on 9,10 dimethyl1,2-benzanthracene (DMBA)-induced mammary tumorigenesis
388. Suppressive effect by melatonin on different phases of 9,10 dimethyl-1,2-benzanthracene (DMBA)-induced rat mammary gland carcinogenesis
389. Effect of the mammary carcinogen 7,12-dimethylbenz(a)anthracene on pineal melatonin biosynthesis, secretion and peripheral metabolism
390. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: A review and tribute to Charles Benton Huggins
391. Biotransformation and bioactivation of 7,12-dimethylbenz(a)anthracene (7,12-DMBA)
392. Activation of ras oncogenes preceding the onset of neoplasia
393. Effect of melatonin on the mammary gland morphology, DNA synthesis, hormone profiles and incidence of mammary cancer in rats
394. Control of breast cancer cell growth by steroids and growth factors: Interactions and mechanisms
395. Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture
396. Reversal by melatonin of the effect of pinealectomy on tumor growth
397. The influence of pineal ablation and administration of melatonin on growth and spread of hamster melanoma
398. Effect of melatonin on hamster melanoma
399. Photoperiodic control of melanoma growth in hamster: Influence of pinealectomy and melatonin
400. Effect of melatonin on B 16 melanoma growth in athymic mice
401. Effects of some low molecular weight sheep pineal fractions and melatonin on different tumors in rats and mice
402. Effect of melatonin on experimental tumors under different photoperiods and times of administration
403. Circadian dependent interleukin-2 tumor growth interaction is favorably modulated by melatonin
404. Pathogenesis of murine leukemia
405. Melatonin-induced immuno-opioids: Role in lymphoproliferative and autoimmune diseases
406. Effects of olfactory bulbectomy, melatonin, and/or pinealectomy on three sublines of the Dunning R 3327 rat prostatic adenocarcinoma
407. Studies on the effects of the pineal hormone melatonin on an androgen-insensitive rat proptotic adenocarcinoma, the Dunning R 3327 HIF tumor
408. Inhibition of Dunning tumor growth by melatonin
409. Effects of melatonin on the growth of MtT/F4 anterior pituitary tumor: Evidence for inhibition of tumor growth dependent upon the time of administration
410. Stress, melatonin and tumor metastasis in mice bearing Lewis lung carcinoma
411. Melatonin and colon carcinogenesis, I: Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats
412. Antiproliferative effects of melatonin and GCP 52608 on the murine Colon 38 adenocarcinoma in vitro and in vivo
413. Influence of melatonin on the proliferation of hepatoma cells in the Syrian hamster: In vivo and in vitro study
414. Effects of growing tumors on pineal melatonin levels in male rats
415. Tumors and the pineal gland
416. The pineal gland in malignancy
417. Inhibition of human breast and endometrial cancer cell growth in culture by the pineal hormone melatonin and its analogue 6-chloromelatonin
418. Antiproliferative effect of pineal indoles on cultured tumor cell lines
419. Growth-inhibiting effect of crude pineal extracts on human melanoma cells in vitro is different from that of known synthetic pineal substances
420. Transcriptional activation of the nuclear receptor RZR by the pineal hormone melatonin and identification of CGP 52608 as a synthetic ligand
421. The effects of melatonin and melatonin analogues on the P388, DLD-1 and MCF-7 tumour cell lines
422. The melatonin rhythm in cancer patients
423. Rationales to consider the use of melatonin as a chrono-oncotherapeutic drug
424. Melatonin in human breast cancer tissue: Association with nuclear grade and estrogen receptor status
425. Nocturnal urinary 6-sulfatoxymelatonin and proliferating cell nuclear antigen-immunopositive tumor cells show strong positive correlations in patients with gastrointestinal and lung cancer
426. Effects of growing tumors on pineal melatonin levels in rats
427. Melatonin therapy of advanced human malignant melanoma
428. Treatment of human metastatic malignant melanoma with high dose oral melatonin
429. Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma: A phase II study
430. Clinical study of melatonin in untreatable advanced cancer patients
431. Clinical results with pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies
432. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates
433. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms
434. Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL- 2 alone
435. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs. chemotherapy with cisplatin and etoposide as first-line therapy for advanced nonsmall cell lung cancer
436. A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast cancer patients
437. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with metastatic solid tumor
438. Modulation of cancer endocrine therapy by melatonin: A phase Il study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone
439. Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer
440. Modulation of tumor necrosis factor-alpha (TNF-alpha) toxicity by the pineal hormone melatonin (MLT) in metastatic solid tumor patients
441. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: A biological phase II study
442. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone
443. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma
444. A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients
445. The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopenia
446. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma
447. Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin
448. Is there a role for melatonin in the treatment of neoplastic cachexia?
449. Immunomodulatory properties of a pineal indole hormone other than melatonin, the 5-methoxytryptophol
450. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state
451. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin
452. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: Efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone
453. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: Preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin
454. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms
455. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status
456. Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: A phase II study
457. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies
458. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms
459. Anti-angiogenic activity of melatonin in advanced cancer patients
460. Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia
461. The validity of melatonin as an oncostatic agent